Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Topamax Launch For Migraine Prevention Includes Unbranded DTC Ad

This article was originally published in The Pink Sheet Daily

Executive Summary

Rollout of Ortho-McNeil's disease awareness ad coincides with sales force launch meeting for the new indication. The ad directs patients to a toll-free phone number and a website.

You may also be interested in...



J&J Weighs Topamax Controlled-Release Formulation After Dropping Obesity Program

Controlled-release topiramate was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release formulation. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says; the formulation remains under evaluation for other indications.

J&J Weighs Topamax Controlled-Release Formulation After Dropping Obesity Program

Controlled-release topiramate was designed to avoid dosing and tolerability issues seen in obesity trials with immediate-release formulation. Phase II study in diabetes-related obesity shows no advantage for long-acting version, J&J says; the formulation remains under evaluation for other indications.

Topamax Promotions Draw FDA Warning Letter For Omitted Safety Information

Agency cites J&J website and sales aid for making tolerability claims without including sufficient risk information.

Related Content

Topics

UsernamePublicRestriction

Register

PS057997

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel